PRANDONI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.770
AS - Asia 11.723
EU - Europa 5.056
AF - Africa 2.208
SA - Sud America 2.125
OC - Oceania 191
Continente sconosciuto - Info sul continente non disponibili 99
Totale 45.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.716
SG - Singapore 3.510
VN - Vietnam 1.773
CN - Cina 1.584
HK - Hong Kong 1.484
BR - Brasile 1.288
FR - Francia 577
FI - Finlandia 574
IT - Italia 500
DE - Germania 362
IN - India 344
SE - Svezia 325
UA - Ucraina 295
BD - Bangladesh 255
PL - Polonia 235
RU - Federazione Russa 228
IQ - Iraq 225
GB - Regno Unito 203
TR - Turchia 186
AR - Argentina 181
PH - Filippine 167
PK - Pakistan 155
JP - Giappone 148
SA - Arabia Saudita 143
ID - Indonesia 141
AT - Austria 122
ZA - Sudafrica 118
MX - Messico 115
NL - Olanda 111
IE - Irlanda 106
CO - Colombia 104
EC - Ecuador 103
UZ - Uzbekistan 100
JO - Giordania 98
AE - Emirati Arabi Uniti 91
ES - Italia 85
CA - Canada 84
TN - Tunisia 83
MA - Marocco 82
AO - Angola 79
CL - Cile 78
MY - Malesia 78
VE - Venezuela 78
KE - Kenya 73
KG - Kirghizistan 73
NP - Nepal 73
AL - Albania 72
TH - Thailandia 69
BG - Bulgaria 67
KZ - Kazakistan 67
KR - Corea 66
EG - Egitto 65
IL - Israele 65
BJ - Benin 64
LV - Lettonia 64
MU - Mauritius 64
PE - Perù 64
PS - Palestinian Territory 64
CZ - Repubblica Ceca 63
DZ - Algeria 63
PY - Paraguay 63
RO - Romania 63
SN - Senegal 63
CY - Cipro 62
DK - Danimarca 61
LB - Libano 61
NO - Norvegia 61
UY - Uruguay 60
CI - Costa d'Avorio 59
ET - Etiopia 59
IR - Iran 59
RE - Reunion 59
BB - Barbados 58
BE - Belgio 58
JM - Giamaica 58
LA - Repubblica Popolare Democratica del Laos 58
LY - Libia 58
TJ - Tagikistan 58
GR - Grecia 57
ME - Montenegro 56
PA - Panama 55
TW - Taiwan 55
AZ - Azerbaigian 54
BO - Bolivia 54
CM - Camerun 54
CW - ???statistics.table.value.countryCode.CW??? 54
GH - Ghana 54
GT - Guatemala 54
PT - Portogallo 54
RS - Serbia 54
UG - Uganda 54
ZW - Zimbabwe 54
GM - Gambi 53
LC - Santa Lucia 53
RW - Ruanda 53
GN - Guinea 52
HN - Honduras 52
MK - Macedonia 52
SO - Somalia 52
BA - Bosnia-Erzegovina 51
Totale 42.709
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Ashburn 2.272
Woodbridge 2.097
Singapore 2.013
San Jose 1.684
Houston 1.574
Hong Kong 1.355
Seattle 1.221
Wilmington 1.202
Ann Arbor 1.184
Jacksonville 1.183
Cambridge 1.060
Chandler 816
Princeton 550
Ho Chi Minh City 497
Boardman 459
Hanoi 390
San Diego 324
Lauterbourg 280
Los Angeles 252
Santa Clara 245
Helsinki 223
Beijing 191
Nanjing 187
Des Moines 175
Roxbury 174
Medford 169
Bytom 143
Dong Ket 141
New York 136
Amman 92
São Paulo 86
Baghdad 85
Da Nang 84
Tashkent 83
Chicago 81
Dublin 81
Tokyo 81
Council Bluffs 78
Guangzhou 74
Luanda 68
Buffalo 67
Bishkek 65
Dakar 63
Cotonou 59
Haiphong 59
Vienna 59
Bridgetown 58
Nairobi 58
Abidjan 54
Kampala 54
Addis Ababa 53
Dushanbe 53
Shenyang 53
Riga 52
Baku 51
Castries 51
Conakry 51
Lahore 51
Sofia 51
Kigali 50
Nanchang 50
Harare 49
Nuremberg 49
Podgorica 49
Libreville 48
London 48
Milan 47
Jeddah 46
Montevideo 46
Rio de Janeiro 46
Riyadh 46
Vientiane 46
Accra 45
Managua 45
Panama City 45
Willemstad 45
Nouakchott 44
Phnom Penh 43
Ulan Bator 43
Antananarivo 42
Hebei 42
Jiaxing 42
Kinshasa 42
Tianjin 42
Cayenne 40
Dar es Salaam 40
Frankfurt am Main 40
Lima 40
Munich 40
San José 40
Tirana 40
Andorra la Vella 39
Bamako 39
Noumea 39
Istanbul 38
Yerevan 38
Johannesburg 37
Niamey 37
Norwalk 37
Totale 29.119
Salva come PNG Salva come JPEG
Nome #
Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism: A Review of the RIETE Registry 435
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score 320
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience 317
Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease. 310
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome 285
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study 277
Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study 275
An unusual finding of massive pulmonary embolism in a patient during treatment with high-dose ibuprofen 265
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines 259
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients 248
Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study 244
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism 244
Low reproducibility of the diagnosis of subsegmental pulmonary embolism in symptomatic patients 235
Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. 231
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 224
Thrombophilia and the risk of post-thrombotic syndrome: Retrospective cohort observation 221
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism 221
A Prospective Cohort Study On Patients Treated With Anticoagulants For Cerebral Vein Thrombosis. 214
Iliopsoas bursitis and femoral vein thrombosis complicating total hip arthroplasty in an elderly patient 214
Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation 213
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study 211
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 211
Cancer and venous thromboembolism 207
Aspirin for preventing the recurrence of venous thromboembolism. 207
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 206
Antithrombotic Therapy for VTE Disease 202
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. 198
Weight-adjusted versus fixed dose heparin thromboprophylaxis in hospitalized obese patients: A systematic review and meta-analysis 198
Double vena cava filter insertion in congenital duplicated inferior vena cava: a case report and literature review. 197
Fondaparinux in the initial and long-term treatment of venous thromboembolism 197
Role of D-dimer monitoring for the diagnosis of deep vein thrombosis in patients undergoing neurosurgery for brain tumor 195
External validation of the simplified Geneva risk assessment model for hospital-associated venous thromboembolism in the Padua cohort 192
Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry 191
A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. 190
Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism 188
How to effectively manage the event of bleeding complications when using anticoagulants 187
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 186
A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity 184
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism 183
Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs 181
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants 180
Treatment of venous thromboembolism: the single-drug approach 178
Adherence to the novel oral anticoagulants: An unmet need 178
A prospective study on survival in cancer patients with and without venous thromboembolism 176
Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism 175
The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. 175
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer 175
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report 175
Venous thrombosis and risk of cancer in patients with arterial cardiovascular disease 175
Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. 174
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies 172
Apixaban for Extended Treatment of Venous Thromboembolism 170
Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism 170
Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism 170
Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study 170
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: New scenarios and opportunities 169
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 169
Cancer Screening in Unprovoked Venous Thromboembolism 169
The post-thrombotic syndrome 168
Approach to Venous Thromboembolism in the Cancer Patient 168
Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. 168
Thrombophilia as a predictor of persistent residual vein thrombosis 167
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update 167
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism 165
Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis. 165
Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism 165
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. 163
Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry 163
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies 162
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. 162
Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. 162
Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism 162
Unsuspected pulmonary embolism in patients with cancer 162
Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. 161
Venous thromboembolism and subsequent diagnosis of subarachnoid haemorrhage: a 20-year cohort study 160
A prospective study on cardiovascular events after acute pulmonary embolism. 160
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 160
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. 160
Optimal duration of anticoagulation: Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests 160
Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders 159
Oral Apixaban for the Treatment of Acute Venous Thromboembolism 159
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 159
Residual pulmonary obstruction and the risk of late complications in patients with pulmonary embolism 159
Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry 159
An international survey on isolated subsegmental pulmonary embolism. 158
Clinical presentation and outcome of venous thromboembolism in COPD 157
Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience 157
Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients 157
Inherited thrombophilia and venous thromboembolism 156
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial 156
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 156
Syncope in Elderly People: A Threatening Presentation of Pulmonary Embolism: A Case Report 156
Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. 156
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. 155
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 154
“Thrombotic aura”: a case report 154
Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. 153
D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer 151
Major bleeding as a predictor of mortality in patients with venous thromboembolism 150
Influence of recent immobilization or surgery on mortality in cancer patients with venous thromboembolism 150
Totale 18.984
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.396
article - articoli 118.648
book - libri 585
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 616
Totale 240.245
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021786 0 0 0 0 0 0 0 0 0 0 418 368
2021/20223.750 103 349 510 248 220 195 127 431 262 90 433 782
2022/20232.033 618 111 27 196 406 245 4 97 197 14 83 35
2023/20241.032 34 124 95 76 94 95 67 30 48 34 184 151
2024/20254.779 17 299 260 152 763 76 206 317 488 197 781 1.223
2025/202620.159 492 2.230 3.107 3.264 1.516 873 2.602 1.850 2.339 1.320 566 0
Totale 45.329